AMARIN CORP PLC\UK Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal)
AMARIN CORP PLC\UK (AMRN) reported Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) of $61.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SalesTypeLeaseImpairmentLoss · last filed 2026-03-02
- AMARIN CORP PLC\UK sales-type lease, net investment in lease, credit loss expense (reversal) for the quarter ending 2023-12-31 was $0.00.
- AMARIN CORP PLC\UK sales-type lease, net investment in lease, credit loss expense (reversal) for the quarter ending 2023-09-30 was $0.00.
- AMARIN CORP PLC\UK sales-type lease, net investment in lease, credit loss expense (reversal) for the quarter ending 2023-06-30 was $0.00.
- AMARIN CORP PLC\UK sales-type lease, net investment in lease, credit loss expense (reversal) for the quarter ending 2023-03-31 was $61.00K.
- AMARIN CORP PLC\UK sales-type lease, net investment in lease, credit loss expense (reversal) for fiscal 2023 was $61.00K.
| Period end | Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) 3 month | Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) 6 month | Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) 9 month | Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $61.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $61.00K 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $61.00K 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $61.00K 10-Q · filed 2024-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |